Program Overview
This corporate program equips participants with deep insights into the principles and application of Good Distribution Practice (GDP) in pharmaceuticals. Delivered by an industry expert with over 25 years of experience, the course blends regulatory expectations, global best practices, and real-world failures to highlight how GDP ensures product quality, traceability, and patient safety across the supply chain. Through case studies, simulations, and hands-on exercises, participants will learn how to manage risks such as temperature excursions, counterfeiting, and audit failures, while aligning with evolving regulatory standards and digital innovations in distribution.
Features
- Interpret global GDP frameworks (EU GDP, WHO, CDSCO, PIC/S) and apply them in practice.
- Identify and mitigate risks in pharmaceutical storage, transport, and distribution.
- Build GDP-compliant SOPs and handle deviations with effective CAPA planning.
- Leverage digital tools (IoT sensors, blockchain, serialization) for GDP compliance and audit readiness.
Target audiences
- Supply Chain & Logistics Teams
- QA/QC & Regulatory Affairs Teams
- Operations Teams
Curriculum
- 5 Sections
- 19 Lessons
- 1 Day
Expand all sectionsCollapse all sections
- Foundations of Pharmaceutical GDP5
- GDP Challenges in Practice4
- 2.1Temperature excursions: cold chain breakdown, vaccine spoilage
- 2.2Cross-border distribution: customs delays, regional GDP gaps (EU vs APAC vs India)
- 2.3Risk points: storage, transport, third-party logistics (3PLs), wholesalers
- 2.4GDP violations and consequences: product recalls, regulatory sanctions, patient risk
- Real-Life Examples & Case Sharing4
- 3.1Case Study 1: Maintaining cold chain for biologics in India’s tier-2 cities
- 3.2Case Study 2: Serialization & anti-counterfeit compliance under EU FMD
- 3.3Case Study 3: Risk-based audits of logistics partners
- 3.4How top pharma companies align GDP with digitalization (IoT sensors, blockchain, digital twins)
- Interactive Exercises & Simulations3
- Wrap-Up & Key Takeaways3